B
Boris Decarolis
Researcher at University of Cologne
Publications - 19
Citations - 351
Boris Decarolis is an academic researcher from University of Cologne. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 7 publications receiving 284 citations.
Papers
More filters
Journal ArticleDOI
Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma
André Oberthuer,Barbara Hero,Frank Berthold,Dilafruz Juraeva,Andreas Faldum,Yvonne Kahlert,Shahab Asgharzadeh,Robert C. Seeger,Paola Scaruffi,Gian Paolo Tonini,Isabelle Janoueix-Lerosey,Olivier Delattre,Gudrun Schleiermacher,Jo Vandesompele,Joëlle Vermeulen,Franki Speleman,Rosa Noguera,Marta Piqueras,Jean Bénard,Alexander Valent,Smadar Avigad,Isaac Yaniv,Axel Weber,Holger Christiansen,Richard Grundy,Katharina Schardt,Manfred Schwab,Roland Eils,Patrick Warnat,Lars Kaderali,Thorsten Simon,Boris Decarolis,Jessica Theissen,Frank Westermann,Benedikt Brors,Matthias Fischer +35 more
TL;DR: Gene expression-based classification using the 144-gene PAM predictor can contribute to improved treatment stratification of neuroblastoma patients.
Journal ArticleDOI
Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
Boris Decarolis,Thorsten Simon,Barbara Krug,Ivo Leuschner,Christian Vokuhl,Peter Kaatsch,Dietrich von Schweinitz,Thomas Klingebiel,I. Mueller,Lothar Schweigerer,Frank Berthold,Barbara Hero +11 more
TL;DR: GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features and Chemotherapy is not effective.
Journal ArticleDOI
Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study
Boris Decarolis,Christina Schneider,Barbara Hero,Thorsten Simon,Ruth Volland,Frederik Roels,Markus Dietlein,Frank Berthold,Matthias Schmidt +8 more
TL;DR: Higher m IBG scores at diagnosis and occurrence of any residual mIBG-positive metastases after four cycles of chemotherapy predicted unfavorable outcome for patients with stage 4 neuroblastoma.
Journal ArticleDOI
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma
Esther M. van Wezel,Janine Stutterheim,Florentien E.M. Vree,Lily Zappeij-Kannegieter,Boris Decarolis,Barbara Hero,Frank Berthold,Roswitha Schumacher-Kuckelkorn,Thorsten Simon,Marta Fiocco,Carlijn Voermans,Max M. van Noesel,Huib N. Caron,C. Ellen van der Schoot,Godelieve A.M. Tytgat +14 more
TL;DR: The clinical significance of minimal residual disease detected by real‐time quantitative PCR (qPCR) in autologous stem cell grafts in high risk neuroblastoma is still controversial and a panel of RNA markers used in this retrospective multicenter study found it to be significant.
Journal ArticleDOI
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel.
Esther M. van Wezel,Lieke M. J. van Zogchel,Jalenka van Wijk,Ilse Timmerman,Ngoc-Kim Vo,Lily Zappeij-Kannegieter,Boris Decarolis,Thorsten Simon,Max M. van Noesel,Jan J. Molenaar,Tim van Groningen,Rogier Versteeg,Huib N. Caron,C. Ellen van der Schoot,Jan Koster,Johan van Nes,Godelieve A.M. Tytgat +16 more
TL;DR: It is proposed that the markers POSTN and PRRX1, in combination with FMO3, be used for real-time quantitative polymerase chain reaction–based detection of MES neuroblastoma mRNA in patient samples because these markers have a unique pattern during treatment and are more prevalent in patients with poor outcome.